Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...

Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

Like many life sciences outfits undergoing a restructuring, Charles River Laboratories is balancing layoffs and a business ...

CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium (CRAC) ...

As Gianakakos, Chief Medical Officer Edelberg and the rest of the Kardigan team continue developing their pipeline through ...

Through Nov. 15 of last year, pharma deal value rose 79% compared to the same period in 2024, according to Bain. The average deal size also climbed more than 80%, “signaling a decisive return of ...

The oncology biotech plans to offer 17,648,000 shares at $17 a pop, according to a Jan. 28 filing with the Securities and Exchange Commission. The maximum price outlined by Eikon is $18 per share, ...

Scientists have discovered a molecule that shrinks brain tumors in mice, raising hopes that the compound could one day become a pill to treat glioblastoma, one of the world’s most pernicious cancers.

Medtech dealmaking rebounded last year, and, in 2026, M&A players are seeking to “outperform the next-best owner” amid softer valuations for assets. | Bain & Company’s new 2026 global M&A report found ...

What was once a barren field five years ago is now in a “virtuous cycle,” a transformation Darsow felt firsthand as the Novo ...

The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial.